Market Place
Sourcing Support
Ocular Therapeutix Accelerated Timelines For SOL-1 Trial In Wet AMD
15 Oct 2024 //
GLOBENEWSWIRE
Clearside`s CLS-AX excels in phase 2b trial, set for phase 3
10 Oct 2024 //
FIERCE PHARMA
Ocular Therapeutix To Present At UBS Ophthalmology Day 2024
25 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Reports Inducement Grant
12 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at September Retina Meetings
05 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ to Present at Two Investor Conferences
04 Sep 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Receives FDA Feedback On SOL-R Trial For Wet AMD
07 Aug 2024 //
GLOBENEWSWIRE
Ocular Therapeutix™ Reports Second Quarter 2024 Results
07 Aug 2024 //
GLOBENEWSWIRE
Ocular Therapeutix Enrolls First Patients In Phase 3 SOL-R Wet AMD Study
30 Jul 2024 //
GLOBENEWSWIRE
ASCO: Merck KGaA`s Bavencio combo misses survival mark in RCC
23 May 2024 //
FIERCE PHARMA
Ocular Therapeutix„ Reports First Quarter 2024 Results
06 May 2024 //
GLOBENEWSWIRE
Clearside Biom Announces Enrollment of Participants in Ph 2b Trial of CLS-AX
17 Jul 2023 //
GLOBENEWSWIRE
China’s NMPA Accepts sNDA for Frontline Toripalimab & Axitinib in Metastatic RCC
12 Jul 2023 //
RAPS
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX
01 Jun 2023 //
GLOBENEWSWIRE
Clearside Biomedical Announces Plans for ODYSSEY Ph 2b Clinical Trial of CLS-AX
18 Apr 2023 //
GLOBENEWSWIRE
Clearside Announces Positive Results from OASIS Extension Study
02 Feb 2023 //
GLOBENEWSWIRE
Ocular Announces Interim 7-month Data from U.S. Phase 1 Trial of OTX-TKI
27 Sep 2022 //
BUSINESSWIRE
Amber Specialty Added to Pfizer’s Limited Distribution Network
03 Aug 2022 //
BUSINESSWIRE
Clearside concludes dosing in Phase I/IIa wet AMD trial
27 Jul 2022 //
CLINICALTRIALSARENA
Clearside Biomedical Completes Dosing in OASIS PI/IIa Trial of CLS-AX in Wet AMD
26 Jul 2022 //
GLOBENEWSWIRE
Clearside Biomedical Announces Positive Safety Results from OASIS Ph 1/2a
21 Dec 2021 //
GLOBENEWSWIRE
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort
02 Mar 2021 //
GLOBENEWSWIRE
Clearside Biomedical Announces CLS-AX Presentation
16 Feb 2021 //
GLOBENEWSWIRE
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a of CLS-AX
12 Jan 2021 //
BIOSPACE
NCCN Announces Research Projects Exploring Axitinib in Various Cancers
15 Dec 2020 //
PRNEWSWIRE
Glenmark receives ANDA tentative approval for Axitinib Tablets, 1 mg and 5 mg
01 Dec 2020 //
INDIAINFOLINE
Glenmark Pharma gets tentative nod from USFDA for cancer treatment drug
30 Nov 2020 //
ECONOMICTIMES
Avelumab with axitinib for untreated advanced renal cell carcinoma
03 Sep 2020 //
NICE
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
28 Aug 2020 //
PHARMATIMES
Clearside Biomedical Announces U.S. FDA Acceptance of iNDA for CLS-AX
10 Aug 2020 //
GLOBENEWSWIRE
NICE Recommends BAVENCIO® (Avelumab) in Combination with Axitinib
31 Jul 2020 //
PRESS RELEASE
Merck, Pfizer terminate Bavencio head and neck cancer trial
16 Mar 2020 //
PHARMATIMES
Genome & Company announces a clinical trial collaboration and supply agreement
13 Jan 2020 //
PR NEWSWIRE
Keytruda combo bags EU approval in RCC
06 Sep 2019 //
PHARMATIMES
MHRA gives Bavencio, Inlyta combo Early Access to Medicines status
22 Jul 2019 //
PHARMATIMES
FDA approval for Bavencio combo in advanced RCC
16 May 2019 //
PHARMA TIMES
Merck claims key FDA okay for Bavencio in kidney cancer
15 May 2019 //
PMLIVE
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination
14 May 2019 //
PR NEWSWIRE
Merck Announces First-Quarter 2019 Financial Results
30 Apr 2019 //
BUSINESSWIRE
Merck`s Keytruda stumbles again in stomach cancer
26 Apr 2019 //
FIERCE PHARMA
Merck`s Keytruda wins FDA approval as combination therapy for kidney cancer
23 Apr 2019 //
REUTERS
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta®
22 Apr 2019 //
BUSINESSWIRE
Keytruda heaps pressure on Opdivo with kidney cancer debut
22 Apr 2019 //
FIERCE PHARMA
Between Merck & Pfizer, the race is on in kidney cancer
19 Feb 2019 //
FIERCE PHARMA
FDA Grants Priority Review to Merck’s sBLA for Keytruda+Inlyta for RCC
15 Feb 2019 //
BIOSPACE
FDA Accepts sBLA & Grants Priority Review for BAVENCIO+INLYTA
13 Feb 2019 //
PR NEWSWIRE
Bavencio combo gets FDA priority review for kidney cancer
13 Feb 2019 //
PHARMA TIMES
Merck, Pfizer combo treatment boosts kidney cancer survival
12 Feb 2019 //
REUTERS
Roche yanks Tecentriq kidney cancer applications as Merck, Pfizer
21 Nov 2018 //
FIERCE PHARMA
Pfizer, Merck KGaA`s Bavencio flunks another trial in Ovarian Cancer
20 Nov 2018 //
FIERCE PHARMA
Merck previews early hit with Keytruda combo for kidney cancer
19 Oct 2018 //
ENDPTS
Novartis, Pfizer, AZ and more hand China 50%-plus cancer drug discounts
11 Oct 2018 //
FIERCE PHARMA
Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive
13 Sep 2018 //
SEEKING ALPHA
Merck KGaA, Pfizer`s immuno-drug shown to alleviate kidney cancer
12 Sep 2018 //
REUTERS
China Unveils Cancer Drugs for Medical Insurance Access Negotiation
21 Aug 2018 //
BIOCENTURY
Teva Pharms` Generic Axitinib Receives Tentative Approval in US
10 Aug 2018 //
FDA
X4 Pharma Reports +ve Clinical Data from Ph 2 Expansion of X4P-001-IO & Axitinib
02 Jun 2018 //
PRESS RELEASE
Inlyta® (Axitinib) Tablets : Pfizer v. Apotex
25 May 2018 //
PATENT LITIGATION
X4 Pharma to Present Clinical Data from Ph2 Expansion Study X4P-001-IO & Inlyta®
16 May 2018 //
PRESS RELEASE
FDA Confirms Paragraph IV Patent Challenge of Inlyta (Axitinib) Tablets
18 Apr 2018 //
FDA
